Indication
Recurrent Prostate Carcinoma
9 clinical trials
8 products
4 drugs
Clinical trial
[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)Status: Recruiting, Estimated PCD: 2027-08-01
Product
[Ac-225]-PSMA-62Product
Ac-225-PSMA-62Clinical trial
Phase 1 Trial to Determine Safety and Feasibility in Treating Biochemical Recurrence Post-Prostatectomy With PSMA PET Guided External Beam Radiotherapy Followed by Consolidative Radioligand TherapyStatus: Recruiting, Estimated PCD: 2028-04-01
Product
Lutetium Lu 177 PSMA-10.1Clinical trial
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2024-06-06
Drug
AN0025Product
OlaparibClinical trial
Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical ProstatectomyStatus: Recruiting, Estimated PCD: 2030-01-22
Product
Antiandrogen TherapyClinical trial
A Prospective Pilot Study Investigating rhPSMA 7.3 PET/MRI in Detecting Recurrent Disease and Aid in Radiotherapy Planning in Patients With Biochemically Recurrent Prostate CancerStatus: Completed, Estimated PCD: 2024-06-04
Product
Fluorine F 18 rhPSMA-7.3Clinical trial
Technology-Enhanced Acceleration of Germline Evaluation for Therapy - The TARGET StudyStatus: Active (not recruiting), Estimated PCD: 2024-09-10
Product
Genetic TestingClinical trial
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate CancerStatus: Completed, Estimated PCD: 2022-12-09
Drug
68Ga-PSMA-11Clinical trial
68Ga-PSMA-11 PET in Patients With Prostate CancerStatus: Recruiting, Estimated PCD: 2024-09-30
Product
Gallium Ga 68 GozetotideClinical trial
Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus RelugolixStatus: Active (not recruiting), Estimated PCD: 2025-01-30
Drug
LHRH agonistDrug
Relugolix